itacitinib   Click here for help

GtoPdb Ligand ID: 8364

Synonyms: Examlpe 294 [WO2011112662] | INCB-039110
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Itacitinib (INCB039110) is a potent and selective inhibitor of Janus kinase 1 (JAK1). Design and synthesis of this compound is claimed in patent WO2011112662 where it is Example 294 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 119.62
Molecular weight 553.2
XLogP 2.28
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES N#CCC1(CN(C1)C1CCN(CC1)C(=O)c1ccnc(c1F)C(F)(F)F)n1ncc(c1)c1ncnc2c1cc[nH]2
Isomeric SMILES N#CCC1(CN(C1)C1CCN(CC1)C(=O)c1ccnc(c1F)C(F)(F)F)n1ncc(c1)c1ncnc2c1cc[nH]2
InChI InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)
Immunopharmacology Comments
Itacitinib (INCB039110) is a potent JAK1 inhibitor that is being evaluated for clinical anti-inflammatory efficacy.
Immunopharmacology Disease
Disease X-Refs Comment References
Pruritus Phase 2 clinical candidate for chronic pruritus (see NCT02909569).
Graft versus host disease Phase 3 clinical candidate for acute GvHD (see NCT03139604).
Myelofibrosis Disease Ontology: DOID:4971
OMIM: 254450
Orphanet: ORPHA824
Phase 2 clinical candidate for myelofibrosis (see NCT03144687).
Psoriasis Disease Ontology: DOID:8893
Phase 2 study NCT01634087 in psoriasis has been completed.
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Phase 2 study NCT01626573 in RA has been completed.